http://eyewiretoday.com/ Newest Articles en-us Fri, 18 May 2012 03:50:37 GMT Fri, 18 May 2012 03:50:37 GMT Eyetube.net http://eyewiretoday.com/view.asp?url=20120517-novabay_enrolls_first_patients_in_global_baynovation_phase_2b_study_for_adenoviral_conjunctivitis NovaBay Pharmaceuticals, Inc., announced that it has enrolled the first patients in its global Phase 2b clinical study. The study (named BAYnovation) will evaluate the company's lead compound, NVC-422, for treating adenoviral conjunctivitis, a highly contagious form of "pink eye."After providing certain suggestions and insight into the design of BAYnovation at an End-of-Phase 2A meeting, the Food and Drug Administration (FDA) confirmed that the trial has all the design elements (controls, sample... Thu, 17 May 2012 14:44:00 GMT http://eyewiretoday.com/view.asp?url=20120517-smartphones_can_help_the_visually_impaired_but_many_doctors_arent_recommending_them iPhones and other smartphones can be a huge help to the visually impaired, but few vision doctors are recommending them to patients, according to a study co-authored by a Loyola University Chicago Stritch School of Medicine ophthalmologist.Researchers surveyed 46 low-vision adults from the Chicago Lighthouse and the Spectrios Institute for Low Vision in Wheaton, Ill. Participants best-corrected vision ranged from 20/70 to complete blindness.Researchers found that only 15 percent of patients repo... Thu, 17 May 2012 13:41:00 GMT http://eyewiretoday.com/view.asp?url=20120517-lutein_zeaxanthin_may_reduce_cataract_risk_study Lutein and Zeaxanthin may protect the lens of the eye from oxidative stress and reduce the risk of cataract, says a new study. The protective effect of Lutein or Zeaxanthin were reported to be similar to those of vitamin E (alpha-tocopherol), according to findings published in Molecular Vision. Thu, 17 May 2012 13:36:00 GMT http://eyewiretoday.com/view.asp?url=20120517-optical_coherence_tomography_useful_for_macular_edema In patients with diabetic macular edema, visual acuity (VA) correlates with the magnitude of change in central macular thickness (CMT). The strongest correlation with VA is the absolute (correlation coefficient, 0.416; P =.016) and relative (correlation coefficient, 0.398; P =.022) change in CMT from baseline to the first laser photocoagulation. CMT taken at a single time point is not as strongly correlated with CMT (correlation coefficient, 0.322; P = .004). Thu, 17 May 2012 13:31:00 GMT http://eyewiretoday.com/view.asp?url=20120516-eye_cancer_tumors_likely_to_spread_can_be_identified_by_genetic_test Researchers at Washington University School of Medicine in St. Louis have developed a genetic test that can accurately predict whether the most common form of eye cancer will spread to other parts of the body, particularly the liver. Wed, 16 May 2012 14:04:00 GMT http://eyewiretoday.com/view.asp?url=20120516-can_plusoptix_replace_cycloplegic_exams_in_young_children? Do children who have had undilated plusoptiX exams also need to have dilated exams to make sure that abnormalities have not been overlooked? That is the fundamental question researchers David Silbert, MD, and Noelle S. Matta, MD, from the Family Eye Group in Lancaster, Pennsylvania, set out to answer. In a retrospective study presented here at the American Association for Pediatric Ophthalmology and Strabismus 38th Annual Meeting, they identified children who had had an undilated plusoptiX exam ... Wed, 16 May 2012 14:02:00 GMT http://eyewiretoday.com/view.asp?url=20120516-genentech_to_test_alzheimers_drug_on_healthy_patients_in_historic_first_prevention_trial Roche's Genentech unit has won the right to try its experimental Alzheimer's drug crenezumab on people with no signs of dementia -- the first such trial to gauge whether early intervention can help prevent or slow the disease. The drug will be tested among members of an extended family of about 5,000 people from the Antioquia region of Colombia. They carry a gene that causes them to develop Alzheimer's early, with some experiencing symptoms of memory loss in their mid-30s, scientists say. Wed, 16 May 2012 13:57:00 GMT http://eyewiretoday.com/view.asp?url=20120516-docs_win_most_malpractice_cases_at_trial Plaintiffs hardly ever win medical malpractice cases that go all the way to a jury verdict, and only 4.5% of claims filed ever go that far, researchers said. Of those that do get to a jury, 79.6% of the verdicts favor the physician, a team led by Anupam Jena, MD, PhD, of Massachusetts General Hospital in Boston found. Wed, 16 May 2012 13:55:00 GMT http://eyewiretoday.com/view.asp?url=20120515-pacific_cataract_and_laser_institute_sees_big_benefits_with_digital_pen_and_paper_technology Anoto and NextGen Healthcare Information Systems LLC announced that Pacific Cataract and Laser Institute is capturing new patient registration information with their joint solution, resulting in more efficient operations and the added benefit of immediate access to patient health history. Pacific Cataract and Laser Institute is a referral center that specializes in cataract surgery and laser vision correction. As a referral center, most of the people they treat are first-time patients. With cata... Tue, 15 May 2012 16:08:00 GMT http://eyewiretoday.com/view.asp?url=20120515-vision_loss_due_to_degenerative_eye_diseases_may_be_restored_by_new_type_of_retinal_prosthesis Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases. Tue, 15 May 2012 13:47:00 GMT http://eyewiretoday.com/view.asp?url=20120515-topical_antibiotics_boost_risk_of_endophthalmitis_after_eye_injections After intravitreal injections of anti-vascular endothelial growth factors or triamcinolone, topical antibiotics might actually be unhelpful, a new paper suggests. The topical antibiotics were associated with an increased risk of infection in a Canadian study reported online April 3 in Ophthalmology. The senior author of the article told Reuters Health he no longer uses them. Tue, 15 May 2012 13:46:00 GMT http://eyewiretoday.com/view.asp?url=20120515-changes_in_eye_vessels_signal_heart_troubles Changes in diameter of the tiny blood vessels in the retina predicted the later development of cardiovascular disease in African Americans with type 1 diabetes, researchers found. Multiple regression analyses determined that baseline narrowing of the central retinal arterioles was independently associated with any incident cardiovascular disease (OR 1.60, 95% CI 1.14 to 2.26, P=0.007) and lower extremity arterial disease (OR 1.94, 95% CI 1.10 to 3.42, P=0.02), according to Monique S. Roy, MD, of... Tue, 15 May 2012 13:39:00 GMT http://eyewiretoday.com/view.asp?url=20120515-carl_zeiss_meditec_continues_its_profitable_growth Medical technology provider Carl Zeiss Meditec generated growth of 14.8% in the first six months of financial year 2011/2012. The company posted revenue of EUR 431.8 million - EUR 56 million more than for the same period of the previous year (EUR 376.0 million). Once again, Carl Zeiss Meditec AG improved its profitability, increasing its earnings before interest and tax (EBIT) by 19 percent to EUR 61.1 million (previous year:EUR 51.3 million). The EBIT margin increased to 14.1% (previous year:13... Tue, 15 May 2012 13:37:00 GMT http://eyewiretoday.com/view.asp?url=20120515-eye_changes_may_predict_heart_disease_in_blacks_with_diabetes In black Americans with type 1 diabetes, narrowing of the small arteries in the eye's retina (retinal arteriolar narrowing) is associated with increased risk for cardiovascular disease, a new study finds. Tue, 15 May 2012 13:33:00 GMT http://eyewiretoday.com/view.asp?url=20120514-bausch__lomb_names_john_barr_global_president_surgical Bausch + Lomb has named John Barr Global President of the company's surgical business. In this capacity, Mr. Barr will oversee the company's full suite of ophthalmic surgical products, IOLs and delivery systems, which include such brand names as enVista Crystalens, Stellaris PC, Storz and VICTUS. John Barr is a seasoned leader with an impressive track record driving business performance at innovation-based companies, said Brent L. Saunders, chief executive officer, Bausch + Lomb. The combinat... Mon, 14 May 2012 18:27:00 GMT http://eyewiretoday.com/view.asp?url=20120514-new_advances_in_treating_inherited_retinal_diseases Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The articles are available free on the Human Gene Therapy website. Mon, 14 May 2012 14:01:00 GMT http://eyewiretoday.com/view.asp?url=20120514-two_glaucoma_implants_equally_good_at_3_years The Ahmed glaucoma valve and the Baerveldt glaucoma implant, the 2 most commonly used glaucoma drainage implants in the United States, are equally successful in the treatment of refractory glaucoma, according to the 3-year results of the Ahmed Baerveldt Comparison (ABC) study. The results were presented here at the Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting by Donald L. Budenz, MD, MPH, professor and chair of the Department of Ophthalmology at the University ... Mon, 14 May 2012 13:59:00 GMT http://eyewiretoday.com/view.asp?url=20120514-lights_on_or_off_for_pediatric_red_reflex_exam? Pediatricians detect ocular disease in infants and children using the red reflex exam, but does it underestimate the presence of that disease? That's what researchers wanted to know when they had 32 participants (younger than 10 years) examined separately by a pediatric ophthalmologist and by 2 pediatricians. Mon, 14 May 2012 13:58:00 GMT http://eyewiretoday.com/view.asp?url=20120514-fda_grants_fast_track_designation_to_ohr_pharmaceuticals_squalamine_eye_drops_for_the_treatment_of_wet_amd Ohr Pharmaceutical Inc. announced that its Squalamine Eye Drops, a potent inhibitor of multiple growth factors implicated in angiogenesis, has been awarded fast track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of the wet form of macular degeneration (wet AMD)."We believe the fast track designation underscores the importance of developing an eye drop for the treatment of wet AMD and its potential to address an unmet medical need for this large and growi... Mon, 14 May 2012 13:56:00 GMT http://eyewiretoday.com/view.asp?url=20120514-new_type_of_retinal_prosthesis_could_better_restore_sight_to_blind_stanford_study_says Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases.This device a new type of retinal prosthesis involves a specially designed pair of goggles, which are equipped with a miniature camera and a pocket PC that is designed to process the visual data stream. The resulting images woul... Mon, 14 May 2012 13:38:00 GMT http://eyewiretoday.com/view.asp?url=20120511-optos_continues_to_demonstrate_strong_clinical_evidence Optos PLC announced the presentation of more than 50 positive clinical studies at ARVO. The clinical studies involved clinical sites from 49 academic institutes in 10 countries. In total, 3,324 patients and 5,376 eyes were studied to investigate the importance of Optos ultra-widefield imaging. The researchers identified positive clinical evidence in 25 different eye diseases using Optos ultra-widefield and optical coherence tomography medical technology. The clinical studies presented include a... Fri, 11 May 2012 18:44:00 GMT http://eyewiretoday.com/view.asp?url=20120511-besifloxacin_demonstrated_potent_activity_high_rate_of_eradication_against_multi-drug_resistant_organisms_that_cause_eye_infections The antibiotic besifloxacin demonstrated potent activity and high rates of eradication against problematic multi-drug resistant organisms that cause eye infections, according to the results of two studies presented today at the 2012 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida. First, in 2011 findings from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study, besifloxacin showed similar in-vitro pot... Fri, 11 May 2012 14:18:00 GMT http://eyewiretoday.com/view.asp?url=20120511-advanced_loteprednol_etabonate_gel_formulation_may_offer_new_option_for_ocular_inflammation Bausch + Lomb announced that its new loteprednol etabonate (LE) gel formulation demonstrated safety and efficacy for the treatment of ocular inflammation after cataract surgery, according to clinical findings presented at the 2012 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Fort Lauderdale, Florida.The advanced loteprednol etabonate gel formulation offers significant benefits for the treatment of ocular inflammation, said Richard DSouza, Vice President of Develo... Fri, 11 May 2012 14:17:00 GMT http://eyewiretoday.com/view.asp?url=20120511-amakem_appoints_dr_steve_pakola_as_chief_medical_officer_dr_george_lasezkay_joins_board_of_directors Amakem NV, a kinase platform company focusing on ophthalmology, today announces the appointment of Dr. Steve Pakola as Chief Medical Officer and Dr. George Lasezkay to its Board as an Independent Director. Both have exceptional track records in the biotechnology industry and bring a wealth of ophthalmology experience to Amakem.Dr. Pakola was previously Chief Medical Officer at ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medic... Fri, 11 May 2012 14:14:00 GMT http://eyewiretoday.com/view.asp?url=20120511-thrombogenics_announces_business_update ThromboGenics signed an important strategic deal with Alcon, the global leader in eye care, to commercialize ocriplasmin outside the U.S. ThromboGenics will receive up to 375 million in upfront and milestone payments plus royalties commensurate with a product that has successfully completed Phase III development and that has been filed for regulatory approval Fri, 11 May 2012 14:09:00 GMT